Injectable Hierarchical Microsphere-Hydrogel System for the Sustained Release of Bupivacaine and Celecoxib in Long-Acting Analgesia
ACS Applied Materials & Interfaces · 24.12.2025 · 17 (51) · 68910-68924
DOI: 10.1021/acsami.5c13130 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 25.11.2025. Verfasst von Bo Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo No. 2 Hospital, Ningbo 315010, PR China. Hauptthemen laut MEDLINE: Celecoxib, Bupivacaine, Microspheres, Hydrogels. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Natural Science Foundation of Ningbo Municipality, National Key Research and Development Program of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Postoperative pain is a common issue after surgical procedures. While peripheral nerve blocks are an effective strategy for postoperative pain management, local anesthetics, although offering potent analgesia with minimal systemic side effects, are limited by their short half-life and rapid clearance. In this study, we developed an injectable microsphere/hydrogel (MS/Gel) composite designed to provide prolonged local anesthesia. The composite consists of poly(lactic-co-glycolic acid) (PLGA) microspheres coloaded with bupivacaine (Bup) and celecoxib (Cel) via electrostatic spraying and incorporated into a thermosensitive gel matrix composed of poloxamer 407 (P407) and hyaluronic acid (HA). The MS/Gel composite exhibited excellent injectability, uniform microsphere distribution, and a biphasic sustained-release profile, significantly reducing the burst release. In vitro evaluations demonstrated that drug release was extended to more than 10 days. Furthermore, in a rat sciatic nerve block model, the MS/Gel significantly prolonged both mechanical and thermal pain thresholds for up to 48 h. Biocompatibility assessments confirmed good cytocompatibility, biodegradability, lack of neurotoxicity, and only a mild, reversible inflammatory response. Overall, the MS/Gel composite presents a promising strategy for postoperative pain management, providing a safe and effective sustained-release system for long-acting local anesthesia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ningbo No. 2 Hospital, Ningbo 315010, PR China.
- Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
- Cixi Institute of Biomedical Engineering, Ningbo 315300, China.
- Health Science Center, Ningbo University, Ningbo 315211, China.
- Zhejiang Key Laboratory of Biopharmaceutical Contact Materials, Ningbo 315201, China.
ORCID-Profile: Xiaowei Chen, Jiantao Zhang
Förderung
- Natural Science Foundation of Ningbo Municipality
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
- Ningbo Municipal Bureau of Science and Technology
Zitieren
APA
Lu, B., Yang, J., Lv, Y., Fan, F., Zhao, Q., Chen, X., Chen, J., Jiang, L., & Zhang, J. (2025). Injectable Hierarchical Microsphere-Hydrogel System for the Sustained Release of Bupivacaine and Celecoxib in Long-Acting Analgesia. ACS Applied Materials & Interfaces, 17(51), 68910-68924. https://doi.org/10.1021/acsami.5c13130
Vancouver
Lu B, Yang J, Lv Y, Fan F, Zhao Q, Chen X, et al. Injectable Hierarchical Microsphere-Hydrogel System for the Sustained Release of Bupivacaine and Celecoxib in Long-Acting Analgesia. ACS Applied Materials & Interfaces. 2025;17(51):68910-68924. doi:10.1021/acsami.5c13130
BibTeX
@article{Lu2025,
author = {Lu, Bo and Yang, Junhui and Lv, Yingying and Fan, Fan and Zhao, Qien and Chen, Xiaowei and Chen, Junping and Jiang, Lei and Zhang, Jiantao},
title = {Injectable Hierarchical Microsphere-Hydrogel System for the Sustained Release of Bupivacaine and Celecoxib in Long-Acting Analgesia},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
volume = {17},
number = {51},
pages = {68910--68924},
doi = {10.1021/acsami.5c13130}
}
EUVIMED